AdvertiseDonate
Sun, Nov 22, 2026New YorkJersey CityNewarkPhiladelphiaBaltimoreBostonWashingtonRichmond
Live Media Online · 594 Dean Street, Brooklyn, NY 11238

Latest stories

  1. ACC Championship Game: Miami and Wake Forest Set for Historic Rematch
  2. UCLA and Indiana Losses Create Big Ten Championship Chaos
  3. Boise State and San Diego State Set for Pac-12 Championship Rematch
  4. Georgia Secures SEC Title Spot While Texas, Tennessee, and Alabama Compete for Final Playoff Seed
  5. Young Google Analyst Achieves Financial Independence Through Extreme Frugality
News · Suffolk County

Stony Brook researcher to study how tumors block immune signals

Min-Guk Cho will use patient-derived organoids to investigate the cGAS-STING pathway in triple-negative breast cancer.

By Julian Schulz ·

Illustration for: Stony Brook researcher to study how tumors block immune signals
Illustration generated for this article, not a news photograph.

Min-Guk Cho has joined the Renaissance School of Medicine at Stony Brook University to investigate how cancer cells disable a specific immune defense mechanism. As an Assistant Professor in the Department of Pharmacological Sciences and a member of the Cancer Center, Cho focuses on the cGAS-STING pathway. This component of the innate immune system provides antiviral and anti-tumor defenses, but tumors often alter or evade these signals to survive.

Cho arrived at Stony Brook in July 2026 after being recruited by Kenneth Shroyer, the chair of Pathology. Shroyer stated that Cho’s research holds promise for developing novel approaches to address tumor cell interactions with the immune microenvironment. Under the leadership of Cancer Center Director Raymond Bergan, the university is expanding its team of researchers to explore molecular solutions to cancer.

Cho’s current research centers on breast cancer, with a specific focus on triple-negative breast cancer. According to the National Cancer Institute, this subtype accounts for approximately 10 percent to 15 percent of all breast cancer cases. It is defined by the absence of three receptor types often found in other breast cancers. Cho is examining why this pathway, which connects DNA damage to immune responses, behaves inconsistently in tumors. In some cases, tumors reduce the expression of pathway components to escape detection. In others, activity is high but does not produce an effective anti-tumor response because downstream signals are suppressed or redirected to benefit the tumor.

Over the next one to two years, Cho plans to identify new molecular regulators of cGAS activation. He intends to use breast cancer mouse models and organoid development to study tumor-immune interactions. Organoids are three-dimensional patient-derived systems that act as smaller versions of an organ. Cho hopes to use these models to investigate individual differences in cancer biology and treatment responses. This approach allows researchers to address biological differences between mouse and human systems and study why individual patients respond differently to the same treatment.

The lab team includes master’s student Eva Atmaca, undergraduates Eshaal Irfan, Tasmina Mahmud, Soyi Kwon, and Mae Suebsanguan, and instructor Ju-Hyun Ahn. The group is interested in how chromatin structure and histone modifications regulate cGAS activation following DNA damage. Cho does not provide clinical care or perform patient diagnoses. His work focuses on understanding biological mechanisms, though he may analyze patient-derived samples for research purposes.

Cho is preparing collaborations with faculty members at the Cancer Center and in the Department of Pharmacological Sciences. He is also working with Shroyer on how the protein keratin 17 modulates the immune response to pancreatic cancer. Cho expects his teaching responsibilities to increase over time. For now, he is participating in select lectures and seminars and plans to contribute to a journal club-style course in the coming semesters.

His long-term goal is to determine whether specific regulators can be targeted through newly developed compounds or existing drugs. He aims to understand how to activate or inhibit specific components of the pathway to improve immune surveillance without benefiting the tumor.

More News · Report a business · Got a Story?

Get Live Media Online in your inboxNews you can follow. Free, a few times a week, unsubscribe any time.

Related stories

Get Live Media Online in your inboxNews you can follow. Free, a few times a week, unsubscribe any time.